PortfoliosLab logoPortfoliosLab logo
LXRX vs. OVID
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LXRX vs. OVID - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lexicon Pharmaceuticals, Inc. (LXRX) and Ovid Therapeutics Inc. (OVID). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, LXRX achieves a 60.87% return, which is significantly higher than OVID's 47.24% return.


LXRX

1D
-2.12%
1M
15.62%
YTD
60.87%
6M
32.14%
1Y
192.72%
3Y*
-12.32%
5Y*
-16.06%
10Y*
-18.68%

OVID

1D
-6.25%
1M
-18.09%
YTD
47.24%
6M
51.90%
1Y
703.48%
3Y*
-13.16%
5Y*
-11.21%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

LXRX vs. OVID - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
LXRX
Lexicon Pharmaceuticals, Inc.
60.87%55.72%-51.73%-19.90%-51.52%15.20%-17.59%-37.50%-32.79%-38.29%
OVID
Ovid Therapeutics Inc.
47.24%74.57%-71.00%73.12%-42.06%38.96%-44.34%71.49%-75.48%-19.43%

Correlation

The correlation between LXRX and OVID is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.34

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (5Y)
Calculated over the trailing 5-year period

0.31

Correlation (All Time)
Calculated using the full available price history since May 8, 2017

0.26

Fundamentals

Market Cap

LXRX:

$740.44M

OVID:

$326.81M

EPS

LXRX:

-$0.07

OVID:

-$0.27

PS Ratio

LXRX:

9.90

OVID:

30.33

PB Ratio

LXRX:

3.65

OVID:

1.65

Total Revenue (TTM)

LXRX:

$69.64M

OVID:

$7.12M

Gross Profit (TTM)

LXRX:

$69.00M

OVID:

$7.06M

EBITDA (TTM)

LXRX:

-$20.38M

OVID:

-$47.25M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Lexicon Pharmaceuticals, Inc.

Ovid Therapeutics Inc.

Often compared with OVID:
OVID vs. ARAAF

Return for Risk

LXRX vs. OVID — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LXRX
LXRX Risk / Return Rank: 8989
Overall Rank
LXRX Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
LXRX Sortino Ratio Rank: 8787
Sortino Ratio Rank
LXRX Omega Ratio Rank: 8383
Omega Ratio Rank
LXRX Calmar Ratio Rank: 9393
Calmar Ratio Rank
LXRX Martin Ratio Rank: 9090
Martin Ratio Rank

OVID
OVID Risk / Return Rank: 9898
Overall Rank
OVID Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
OVID Sortino Ratio Rank: 9797
Sortino Ratio Rank
OVID Omega Ratio Rank: 9595
Omega Ratio Rank
OVID Calmar Ratio Rank: 9999
Calmar Ratio Rank
OVID Martin Ratio Rank: 9999
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LXRX vs. OVID - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Ovid Therapeutics Inc. (OVID). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LXRXOVIDDifference

Sharpe ratio

Return per unit of total volatility

2.26

6.48

-4.22

Sortino ratio

Return per unit of downside risk

2.87

4.81

-1.94

Omega ratio

Gain probability vs. loss probability

1.34

1.59

-0.25

Calmar ratio

Return relative to maximum drawdown

5.69

21.13

-15.44

Martin ratio

Return relative to average drawdown

12.51

53.07

-40.57

LXRX vs. OVID - Sharpe Ratio Comparison

The current LXRX Sharpe Ratio is 2.26, which is lower than the OVID Sharpe Ratio of 6.48. The chart below compares the historical Sharpe Ratios of LXRX and OVID, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


LXRXOVIDDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.26

6.48

-4.22

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.16

-0.14

-0.02

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.19

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.17

-0.19

+0.02

Drawdowns

LXRX vs. OVID - Drawdown Comparison

The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum OVID drawdown of -98.30%. Use the drawdown chart below to compare losses from any high point for LXRX and OVID.


Loading charts...

Drawdown Indicators


LXRXOVIDDifference

Max Drawdown

Largest peak-to-trough decline

-99.91%

-98.30%

-1.61%

Max Drawdown (1Y)

Largest decline over 1 year

-34.09%

-34.78%

+0.69%

Max Drawdown (3Y)

Largest decline over 3 years

-91.83%

-93.69%

+1.86%

Max Drawdown (5Y)

Largest decline over 5 years

-95.25%

-94.32%

-0.93%

Max Drawdown (10Y)

Largest decline over 10 years

-98.48%

Current Drawdown

Current decline from peak

-99.44%

-84.00%

-15.44%

Average Drawdown

Average peak-to-trough decline

-93.20%

-75.10%

-18.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.48%

13.82%

+1.66%

Volatility

LXRX vs. OVID - Volatility Comparison

Lexicon Pharmaceuticals, Inc. (LXRX) has a higher volatility of 29.25% compared to Ovid Therapeutics Inc. (OVID) at 17.65%. This indicates that LXRX's price experiences larger fluctuations and is considered to be riskier than OVID based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LXRXOVIDDifference

Volatility (1M)

Calculated over the trailing 1-month period

29.25%

17.65%

+11.60%

Volatility (6M)

Calculated over the trailing 6-month period

58.59%

58.76%

-0.17%

Volatility (1Y)

Calculated over the trailing 1-year period

85.81%

113.47%

-27.66%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

98.26%

79.90%

+18.36%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

97.22%

85.73%

+11.49%

Dividends

LXRX vs. OVID - Dividend Comparison

Neither LXRX nor OVID has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

LXRX vs. OVID - Financials Comparison

This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Ovid Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
21.10M
0
(LXRX) Total Revenue
(OVID) Total Revenue
Values in USD except per share items

Frequently Asked Questions


LXRX and OVID have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

LXRX has higher volatility (29.25%) compared to OVID (17.65%). In terms of maximum drawdown, LXRX dropped -99.91% vs OVID's -98.30%.

OVID currently has the higher Sharpe Ratio (6.48 vs 2.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LXRX and OVID

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer